Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Strasser-Weippl, K; Horick, N; Smith, IE; O'Shaughnessy, J; Ejlertsen, B; Boyle, F; Buzdar, AU; Fumoleau, P; Gradishar, W; Martin, M; Moy, B; Piccart-Gebhart, M; Pritchard, KI; Lindquist, D; Rappold, E; Finkelstein, DM; Goss, PE.

Long-term hazard of recurrence in HER2+breast cancer patients untreated with anti-HER2 therapy

BREAST CANCER RESEARCH. 2015; 17: Nº de citas: 24 [doi:10.1186/s13058-015-0568-1]

Marquez-Rodas, I; Gonzalez, MM; Nagore, E; Gomez-Fernandez, C; Aviles-Izquierdo, JA; Maldonado-Seral, C; Soriano, V; Majem-Tarruella, M; Palomar, V; Maseda, R; Martin-Carnicero, A; Puertolas, T; Godoy, E; Cerezuela, P; de Olza, MO; Campos, B; Perez-Ruiz, E; Soria, A; Gil-Arnaiz, I; Gonzalez-Cao, M; Galvez, E; Arance, A; Belon, J; de la Cruz-Merino, L; Martin-Algarra, S.

Frequency and Characteristics of Familial Melanoma in Spain: The FAM-GEM-1 Study

PLoS One. 2015; 10(4): Nº de citas: 7 [doi:10.1371/journal.pone.0124239]

Garcia-Alfonso, P; Garcia-Foncillas, J; Salazar, R; Perez-Segura, P; Garcia-Carbonero, R; Musulen-Palet, E; Cuatrecasas, M; Landolfi, S; Cajal, SRY; Navarro, S.

Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

CLINICAL & TRANSLATIONAL ONCOLOGY. 2015; 17(4): 264-273 Nº de citas: 10 [doi:10.1007/s12094-014-1252-0]

Boyle, FM; Smith, IE; O'Shaughnessy, J; Ejlertsen, B; Buzdar, AU; Fumoleau, P; Gradishar, W; Martin, M; Moy, B; Piccart-Gebhart, M; Pritchard, KI; Lindquist, D; Amonkar, M; Huang, YJ; Rappold, E; Williams, LS; Wang-Silvanto, J; Kaneko, T; Finkelstein, DM; Goss, PE.

Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer

EUROPEAN JOURNAL OF CANCER. 2015; 51(6): 685-696 Nº de citas: 12 [doi:10.1016/j.ejca.2015.02.005]

Manso, L; Moreno, F; Marquez, R; Castelo, B; Arcediano, A; Arroyo, M; Ballesteros, AI; Calvo, I; Echarri, MJ; Enrech, S; Gomez, A; del Val, RG; Lopez-Miranda, E; Martin-Angulo, M; Martinez-Janez, N; Olier, C; Zamora, P.

Use of bevacizumab as a first-line treatment for metastatic breast cancer

Current Oncology. 2015; 22(2): 51-60 Nº de citas: 16 [doi:10.3747/co.22.2210]

Gruenberger, T; Bridgewater, J; Chau, I; Alfonso, PG; Rivoire, M; Mudan, S; Lasserre, S; Hermann, F; Waterkamp, D; Adam, R.

Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial

ANNALS OF ONCOLOGY. 2015; 26(4): 702-708 Nº de citas: 288 [doi:10.1093/annonc/mdu580]

Garcia-Gonzalez, X; Cortejoso, L; Garcia, MI; Garcia-Alfonso, P; Robles, L; Gravalos, C; Gonzalez-Haba, E; Marta, P; Sanjurjo, M; Lopez-Fernandez, LA.

Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer

Oncotarget. 2015; 6(8): 6422-6430 Nº de citas: 52 [doi:10.18632/oncotarget.3289]

Martin, M; Loibl, S; von Minckwitz, G; Morales, S; Martinez, N; Guerrero, A; Anton, A; Aktas, B; Schoenegg, W; Munoz, M; Garcia-Saenz, JA; Gil, M; Ramos, M; Margeli, M; Carrasco, E; Liedtke, C; Wachsmann, G; Mehta, K; De la Haba-Rodriguez, JR.

Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study

JOURNAL OF CLINICAL ONCOLOGY. 2015; 33(9): 1045 Nº de citas: 99 [doi:10.1200/JCO.2014.57.2388]

Sotelo, MJ; Sastre, J; Maestro, ML; Veganzones, S; Vieitez, JM; Alonso, V; Gravalos, C; Escudero, P; Vera, R; Aranda, E; Garcia-Alfonso, P; Gallego-Plazas, J; Lopez, C; Pericay, C; Arrivi, A; Vicente, P; Ballesteros, P; Elez, E; Lopez-Ladron, A; Diaz-Rubio, E.

Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer

ANNALS OF ONCOLOGY. 2015; 26(3): 535-541 Nº de citas: 66 [doi:10.1093/annonc/mdu568]

Casla, S; Hojman, P; Marquez-Rodas, I; Lopez-Tarruella, S; Jerez, Y; Barakat, R; Martin, M.

Running away from side effects: physical exercise as a complementary intervention for breast cancer patients

CLINICAL & TRANSLATIONAL ONCOLOGY. 2015; 17(3): 180-196 Nº de citas: 47 [doi:10.1007/s12094-014-1184-8]

Tanic, M; Yanowski, K; Gomez-Lopez, G; Rodriguez-Pinilla, MS; Marquez-Rodas, I; Osorio, A; Pisano, DG; Martinez-Delgado, B; Benitez, J.

MicroRNA expression signatures for the prediction of BRCA1/2 mutation-associated hereditary breast cancer in paraffin-embedded formalin-fixed breast tumors

INTERNATIONAL JOURNAL OF CANCER. 2015; 136(3): 593-602 Nº de citas: 39 [doi:10.1002/ijc.29021]

Kamieniak, MM; Rico, D; Milne, RL; Munoz-Repeto, I; Ibanez, K; Grillo, MA; Domingo, S; Borrego, S; Cazorla, A; Garcia-Bueno, JM; Hernando, S; Garcia-Donas, J; Hernandez-Agudo, E; Cajal, TRY; Robles-Diaz, L; Marquez-Rodas, I; Cusido, M; Saez, R; Lacambra-Calvet, C; Osorio, A; Urioste, M; Cigudosa, JC; Paz-Ares, L; Palacios, J; Benitez, J; Garcia, MJ.

Deletion at 6q24.2-26 predicts longer survival of high-grade serous epithelial ovarian cancer patients

MOLECULAR ONCOLOGY. 2015; 9(2): 422-436 Nº de citas: 18 [doi:10.1016/j.molonc.2014.09.010]

Martin, M; Martinez, N; Ramos, M; Calvo, L; Lluch, A; Zamora, P; Munoz, M; Carrasco, E; Caballero, R; Garcia-Saenz, JA; Guerra, E; Caronia, D; Casado, A; Ruiz-Borrego, M; Hernando, B; Ignacio Chacon, J; De la Torre-Montero, JC; Jimeno, MA; Heras, L; Alonso, R; De la Haba, J; Pita, G; Constenla, M; Gonzalez-Neira, A.

Standard Versus Continuous Administration of Capecitabine in Metastatic Breast Cancer (GEICAM/2009-05): A Randomized, Noninferiority Phase II Trial With a Pharmacogenetic Analysis

ONCOLOGIST. 2015; 20(2): 111-112 Nº de citas: 18 [doi:10.1634/theoncologist.2014-0379]

Mackey, JR; Ramos-Vazquez, M; Lipatov, O; McCarthy, N; Krasnozhon, D; Semiglazov, V; Manikhas, A; Gelmon, KA; Konecny, GE; Webster, M; Hegg, R; Verma, S; Gorbunova, V; Gerges, DA; Thireau, F; Fung, H; Simms, L; Buyse, M; Ibrahim, A; Martin, M.

Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer

JOURNAL OF CLINICAL ONCOLOGY. 2015; 33(2): 141-38 Nº de citas: 101 [doi:10.1200/JCO.2014.57.1513]

Pineda, S; Gomez-Rubio, P; Picornell, A; Bessonov, K; Marquez, M; Kogevinas, M; Real, FX; Van Steen, K; Malats, N.

Framework for the Integration of Genomics, Epigenomics and Transcriptomics in Complex Diseases

HUM HERED. 2015; 79(3-4): 124-136 Nº de citas: 14 [doi:10.1159/000381184]

Rosmarin, D; Palles, C; Pagnamenta, A; Kaur, K; Pita, G; Martin, M; Domingo, E; Jones, A; Howarth, K; Freeman-Mills, L; Johnstone, E; Wang, HT; Love, S; Scudder, C; Julier, P; Fernandez-Rozadilla, C; Ruiz-Ponte, C; Carracedo, A; Castellvi-Bel, S; Castells, A; Gonzalez-Neira, A; Taylor, J; Kerr, R; Kerr, D; Tomlinson, I.

A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS

GUT. 2015; 64(1): 111-120 Nº de citas: 94 [doi:10.1136/gutjnl-2013-306571]

Martinez-Laperche, C; Noriega, V; Kwon, M; Balsalobre, P; Gonzalez-Rivera, M; Serrano, D; Anguita, J; Gayoso, J; Diez-Martin, JL; Buno, I.

Achievement of early complete donor chimerism in CD25(+)-activated leukocytes is a strong predictor of the development of graft-versus-host-disease after stem cell transplantation

EXP HEMATOL. 2015; 43(1): 4-13 Nº de citas: 4 [doi:10.1016/j.exphem.2014.09.003]

Martin, M; Herrero, A; Echavarria, I.

BREAST CANCER

ARBOR-CIENCIA PENSAMIENTO Y CULTURA. 2015; 191(773): Nº de citas: 8 [doi:10.3989/arbor.2015.773n3004]